Find something to look at
Browse by category, see the connections as a graph, check out what's being tested in patients right now, or see the latest FDA approvals.
Disease ↔ gene ↔ drug
See the connections as a graph
Three things connect everything: diseases, the genes involved in them, and the drugs that act on those genes. Pick a disease and we'll draw the picture: which genes drive it, and which existing drugs hit those genes.
By category
Pick a body system or disease family. Click any condition to see drugs that might also help it.
Cancer
Solid tumors, blood cancers, and rare oncology.
Heart & vessels
Cardiovascular disease, blood pressure, clotting.
Brain & nerves
Neurodegeneration, dementia, movement, headache.
Mental health
Mood, anxiety, attention, addiction.
Immune & autoimmune
When the body's defenses go wrong.
Metabolism & weight
Diabetes, obesity, thyroid, liver, hormones.
Drugs being tested in patients right now
The most-recent Phase II / Phase III studies that are actively recruiting people. Pulled live from ClinicalTrials.gov.
- Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemi…PHASE3For: Mild Disabling Acute Ischemic StrokeCombination GroupControl GroupNCT07369999● recruiting
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisPHASE3For: Secondary Progressive Multiple SclerosisOrelabrutinibPlaceboNCT07299019● recruiting
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembr…PHASE3For: Endometrial CancerPembrolizumabCarboplatinPaclitaxelDocetaxelNCT06952504● recruiting
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (…PHASE3For: Severe AsthmaGB-0895PlaceboNCT07276724● recruiting
- Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncont…PHASE3For: Chronic Kidney Disease(CKD), Uncontrolled HypertensionAntihypertensive algori…Standard of careNCT05732727● recruiting
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosisPHASE3For: Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression +2 moreRosuvastatin 20 Mg Oral…Colchicine 0.5 MG Oral…PlaceboNCT07232069● recruiting
- A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-01…PHASE3For: Non-small Cell Lung CancerCalderasibDurvalumabNCT07554339● recruiting
- A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyPHASE3For: Epileptic Encephalopathy, SCN2A Encephalopathy1mg elsunersen0.5mg elsunersenNCT07019922● recruiting
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor…PHASE3For: Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer +4 moreFirmonertinibEGFR-TKI inhibitor base…NCT07185997● recruiting
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)PHASE3For: Von Hippel-Lindau Disease, Malignant NeoplasmsBelzutifanNivolumabLenvatinibCabozantinibNCT07405164● recruiting
- A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Re…PHASE3For: Myeloma MultipleBCD-248 + daratumumabDaratumumab + pomalidom…NCT07742215● recruiting
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Su…PHASE2, PHASE3For: Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma +5 moreNivolumabRelatlimabNCT05987241● recruiting
Notable recent FDA approvals
A hand-picked tour of new medicines that reached patients in the last couple of years. Click into any one to see what else it might also help.
Leqembi
2023lecanemabApproved for early Alzheimer's disease.First antibody to slow Alzheimer's progression, by clearing amyloid plaques from the brain.
See its profile →Kisunla
2024donanemabApproved for early Alzheimer's disease.Second-generation amyloid antibody — limited-duration treatment, stops once plaques clear.
See its profile →Rezdiffra
2024resmetiromApproved for advanced fatty liver disease (MASH).First drug ever approved for non-alcoholic steatohepatitis — a condition affecting tens of millions.
See its profile →Zepbound
2023tirzepatideApproved for obesity.GLP-1/GIP dual receptor agonist; the most effective weight-loss medication in trials to date.
See its profile →Winrevair
2024sotaterceptApproved for pulmonary arterial hypertension.First-in-class activin signaling inhibitor for a rare, progressive lung condition.
See its profile →Amtagvi
2024lifileucelApproved for advanced melanoma.First cellular therapy for a solid tumor — uses the patient's own T cells against the cancer.
See its profile →Truqap
2023capivasertibApproved for HR+/HER2- breast cancer.Targets the AKT pathway in tumors that have become resistant to hormone therapy.
See its profile →Wegovy
2024semaglutideApproved for cardiovascular risk reduction.Already approved for obesity; new indication shows it cuts heart-attack risk in overweight adults.
See its profile →